Literature DB >> 35634426

Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study.

Ha Il Kim1, Jihyun An2, Ji Yoon Kim3, Hyun Phil Shin1, Seo Young Park4, Gi-Won Song5,6, Han Chu Lee3,5, Ju Hyun Shim3,5.   

Abstract

Introduction: In spite of the high frequency of recurrence of hepatocellular carcinoma (HCC) after resection, little evidence exists to directly help to plan a reasonable schedule for the frequency and intensity of postoperative surveillance for recurrence.
Methods: 1,918 consecutive patients with Child-Turcott-Pugh class A who had T1- or T2-staged HCCs detected by active surveillance and underwent curative resection for their tumors at 3 teaching hospitals in Korea, followed by recurrence screening at 6-monthly or shorter intervals. To set an evidence-based timetable for postoperative surveillance, we investigated the annual hazard rate of recurrence through postoperative year 10 in patients undergoing hepatectomy for HCC, and the clinical and morphological phenotypes associated with early versus late recurrence.
Results: The estimated hazard rate for recurrence peaked during year 0-1 (21.7%), with a subsequent gradual decrease through 5 years, followed by stabilization at <7.0% until year 10, except in the case of cirrhotics, who had a rate of 10.5% during year 4-5. Multivariate time-to-recurrence analysis by recurrence period revealed that serum alpha-fetoprotein ≥200 ng/mL, larger size of tumor, tumor multiplicity, microvascular invasion, capsular invasion, and higher METAVIR fibrosis stage were significantly related to disease recurrence within 5 years after resection, while cirrhosis (METAVIR F4) alone was related to disease recurrence beyond 5 years (Ps < 0.05). Post-relapse overall survival was better in the latter group (p = 0.033). Conclusions: Our chronological and morphological insights into recurrence after resection of primary HCCs may help implement an optimal intensity of surveillance for recurrence.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Liver cancer; Outcome; Resection; Surveillance

Year:  2021        PMID: 35634426      PMCID: PMC9109079          DOI: 10.1159/000518837

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   12.430


  43 in total

1.  An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

Authors:  P Bedossa; T Poynard
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

Review 2.  Risk factors for hepatocellular carcinoma.

Authors:  D Alan Herbst; K Rajender Reddy
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

3.  Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Daniel A Anaya; Robert Anders; Chandrakanth Are; Melinda Bachini; Mitesh Borad; Daniel Brown; Adam Burgoyne; Prabhleen Chahal; Daniel T Chang; Jordan Cloyd; Anne M Covey; Evan S Glazer; Lipika Goyal; William G Hawkins; Renuka Iyer; Rojymon Jacob; R Kate Kelley; Robin Kim; Matthew Levine; Manisha Palta; James O Park; Steven Raman; Sanjay Reddy; Vaibhav Sahai; Tracey Schefter; Gagandeep Singh; Stacey Stein; Jean-Nicolas Vauthey; Alan P Venook; Adam Yopp; Nicole R McMillian; Cindy Hochstetler; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2021-05-01       Impact factor: 11.908

Review 4.  Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.

Authors:  Fasiha Kanwal; Amit G Singal
Journal:  Gastroenterology       Date:  2019-04-12       Impact factor: 22.682

5.  Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.

Authors:  Vincenzo Mazzaferro; Raffaele Romito; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sherrie Bhoori; Lorenzo Capussotti; Fulvio Calise; Riccardo Pellicci; Giulio Belli; Alessandro Tagger; Massimo Colombo; Ferruccio Bonino; Pietro Majno; Josep M Llovet
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

6.  Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.

Authors:  Koji Uchino; Ryosuke Tateishi; Shuichiro Shiina; Miho Kanda; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

Review 7.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

8.  Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience.

Authors:  Qiang Li; Huikai Li; Yu Qin; P Peter Wang; Xishan Hao
Journal:  J Gastroenterol Hepatol       Date:  2007-11       Impact factor: 4.029

Review 9.  Current status and strategies for hepatitis B control in Korea.

Authors:  Eun Ju Cho; Sung Eun Kim; Ki Tae Suk; Jihyun An; Soung Won Jeong; Woo Jin Chung; Yoon Jun Kim
Journal:  Clin Mol Hepatol       Date:  2017-09-19

Review 10.  Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Authors:  Ibrahim A Hanouneh; Naim Alkhouri; Amit G Singal
Journal:  Clin Mol Hepatol       Date:  2019-03-04
View more
  2 in total

1.  Regarding "Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study".

Authors:  Hiroshi Imamura; Kiyoshi Hasegawa; Yuji Soejima; Akio Saiura
Journal:  Liver Cancer       Date:  2022-05-13       Impact factor: 12.430

Review 2.  Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment.

Authors:  Dimitrios Papaconstantinou; Diamantis I Tsilimigras; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2022-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.